PharmaCyte Biotech : Change in Certifying Accountants - Form 8-K
November 09, 2023 at 07:00 pm EST
Share
Item 4.01.Changes in Registrant's Certifying Accountant.
As previously disclosed, on August 1, 2023, PharmaCyte Biotech, Inc. (the "Company") was informed by Armanino LLP ("Armanino"), the Company's then current independent registered public accounting firm, that Armanino would resign as the Company's independent auditor (not related to any actions taken by the Company). Armanino advised the Company that its decision to resign was due solely to Armanino's decision to exit from the practice of providing financial statement audit services to all its public company engagements.
On November 5, 2023, the Company engaged Marcum LLP ("Marcum") as its new independent registered public accounting firm.
During the two fiscal years ended December 31, 2021 and 2022, and the subsequent interim period through November 5, 2023, the Company has not consulted with Marcum regarding either: (i) the application of accounting principles to any specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements; or (ii) any matter that was either the subject of a disagreement (as defined in Regulation S-K, Item 304(a)(1)(iv) and the related instructions) or reportable event (as defined in Regulation S-K, Item 304(a)(1)(v)).
PharmaCyte Biotech Inc. published this content on 09 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 November 2023 23:59:03 UTC.
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
PHARMACYTE BIOTECH, INC. 
